Showing results (161-170 of 229) with videos related to

Sort By:
Pageof 23
Lancet (London, England)|February 24, 2001
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaI Vergote, J De Brabanter, A Fyles, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2007
Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomasA Coosemans, S Amini Nik, S Caluwaerts, et al.
Breast Cancer Research and Treatment|February 11, 2018
Breast cancer subtype and survival by parity and time since last birthH De Mulder, A Laenen, H Wildiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activationS Bondong, H Kiefel, T Hielscher, et al.
British Journal of Cancer|October 20, 2011
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancerG Hofstetter, A Berger, E Schuster, et al.
Gynecologic Oncology|July 24, 2013
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD studyG Hofstetter, N Concin, I Braicu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseN Colombo, C Sessa, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2013
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyC Fotopoulou, I Vergote, P Mainwaring, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2012
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTGK Lindemann, R D Christensen, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
Pageof 23